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Campomanesia xanthocarpa is known in Brazil as Guabiroba and is popularly used for various diseases, such as inflammatory,
renal, and digestive diseases and dyslipidemia. The aim of the study was to analyze the chemical composition and investigate the
effects of aqueous extract of C. xanthocarpa on the blood pressure of normotensive rats, analyzing the possible action mechanism
using experimental and in silico procedures. The extract was evaluated for total phenolic compounds and total flavonoid content.
The chemical components were determined by HPLC analyses. Systolic and diastolic blood pressure and heart rate were measured
with extract and drugs administration. The leaves of C. xanthocarpa presented the relevant content of phenolics and flavonoids,
and we suggested the presence of chlorogenic acid, gallic acid, quercetin, and theobromine. The acute administration of aqueous
extract of C. xanthocarpa has a dose-dependent hypotensive effect in normotensive rats, suggesting that the action mechanism
may be mediated through the renin-angiotensin system by AT1 receptor blockade and sympathetic autonomic response. Docking
studies showed models that indicated an interaction between chlorogenic acid and quercetin with the AT1 receptor (AT1R) active
site.The findings of these docking studies suggest the potential ofC. xanthocarpa constituents for use as preventive agents for blood
pressure.
1. Introduction
Essential hypertension is a highly prevalent pathological
condition that is considered one of the most relevant cardio-
vascular risk factors and is an important cause of morbidity
and mortality around the world. Major effects on renal and
cardiovascular physiology attributed to angiotensin II are
mediated through the AT1R [1]. Chronic activation of the
AT1R can lead to disease states, including hypertension, car-
diac arrhythmia, stroke, diabetic nephropathy, andmetabolic
disorders [2–4]. The AT1a receptor is well expressed in most
cardiovascular tissues and is the principal regulator of blood
pressure [5], which is effectively treated using AT1R blockers
[4, 6, 7].
Many synthetic drugs have been widely used for the
treatment of hypertension, but herbal medicines still remain
a popular choice. The abundant use of these medicinal plants
has led to extensive research in this area to determine their
potential efficacy, and modern cardiovascular drugs are now
available as natural products [8].
In Brazil, Campomanesia xanthocarpa (Myrtaceae), pop-
ularly known as “Guabiroba,” possesses a wide spectrum
of physiological effects. The leaves of this plant are used
as an infusion in folk medicine to treat inflammatory,
urinary, and rheumatic diseases, and hypercholesterolemia
[9]. Moreover, it is empirically used for weight loss and for
the control of many conditions associated with obesity [10].
Scientific studies demonstrate that C. xanthocarpa extract
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presents mutagenic potential, synergistic effects that result in
comutagenic activity [11], has antiproliferative and genotoxic
activities using the in vivo Allium cepa root-tip cell test and
an increase in the frequency of chromosome aberrations [12],
has antiplatelet, antithrombotic, and fibrinolytic activities,
may be effective in preventing thrombus formation through
several pathways [13], reducing blood cholesterol levels [14],
has a gastroprotective effect [15], and reduces oxidative stress
and inflammatory processes [16, 17]; it may therefore have
therapeutic applications.
Natural biological active compounds in plants have a
significant role in vegetable defense mechanism and are also
important for their unambiguous physiological actions in
human body. Due to their therapeutic properties, secondary
metabolites (flavonoids, alkaloids, tannins, saponins, and
terpenoids) are becoming a part of the integrative health care
system as supportive and alternative medicines [18]. Thus,
knowing the chemical composition of these medicinal plants
is very important.
Phytochemical analysis from the leaves of C. xantho-
carpa extract indicated the presence of flavonoids, saponins,
tannins, and terpenes [12, 14, 15]; these compounds have
known biological potential. Thus, the objective of this study
is to investigate the chemical composition of C. xanthocarpa
extract, evaluate the hemodynamic parameters, and investi-
gate the action mechanism of the aqueous extract in rats by
experimental and in silico procedures (docking analysis).
2. Material and Methods
2.1. Plant Material. Campomanesia xanthocarpa was col-
lected in July 2014 in Uruguaiana/RS (Brazil). The materials
were identified, and a voucher specimen was deposited
at the Herbarium of Universidade Federal do Pampa–Sa˜o
Gabriel/RS.
2.2. Extract Preparation. The leaves were selected, dried at a
temperature of 40∘C, ground, and submitted to an infu-
sion using distilled water at a temperature of 100∘C (1 : 10,
plant : solvent), used in chromatographic assays.
For biological analysis, the infusions were oven-dried,
reduced to powder, and rediluted in 0.9% saline solution for
administration.
2.3. Characterization of Plants and Extracts
2.3.1. Total Phenolic Content. The Folin-Ciocalteu colorimet-
ric method with some modifications was used to determine
the total phenolic content [19]. To a test tube were added
100 𝜇L of the sample, 500 𝜇L of Folin-Ciocalteu, and 6mL of
water; the tube was agitated and left to rest for one minute.
Two milliliters of Na
2
CO
3
solution 15% was added after
alkalizing the medium, and the volume was completed to
10mLwith distilled water. It was read in a spectrophotometer
Perkin Elmer UV-VIS Lambda 35 (Norwalk, CT, USA) at a
wavelength of 750 nm after 30 minutes at room temperature
and protected from light. The total phenolic content was
expressed in milligrams of gallic acid equivalent per mL of
sample (mgGAE/mL).
2.3.2. Total Flavonoid Content. The method described by
Chang et al. [19] was used with some modifications to
determine the total flavonoid content. To a 25mL flask were
added 500𝜇L of the sample and 500 𝜇L of AlCl
3
0.5%, and
the volume was completed with water. The reading was done
in a Lambda 35 Perkin Elmer UV-VIS spectrophotometer
(Norwalk, CT, USA) at a wavelength of 415 nm after being
incubated for 40 minutes at room temperature and protected
from light. The results were expressed in rutin mg equiva-
lents/g (mgRE/g).
2.4. HPLC-DADAssay. Chromatographic analyses were per-
formedusing aProminence ShimadzuHPLC system (Kyoto,
Japan) equipped with an LC-20AT pump, SIL-20A autoin-
jector, SPD-20AT detector, CTO-20A column oven, and
LC Solution V. 1 : 24 SP1 software. The chromatographic
separation was performed in a RP-C18 column Hypersil C18
Thermo-Scientific (250× 4.0mm, 5𝜇m)using amobile phase
of 5% (v/v) acetonitrile (solvent A) or 50% (v/v) acetonitrile
(solvent B) containing 0.05% (v/v) phosphoric acid (85%),
with a 1mL/min flow rate, Diode Array Detector (DAD)
at 280 nm and 340 nm, and an injection volume of 40𝜇L.
The gradient was programmed as follows: solvent A was
maintained at 90%, and solvent B was maintained at 10%
within the first 14 minutes. B increased linearly from 10% to
15% over 14–20 minutes, and this condition was maintained
for four minutes. B increased linearly from 15% to 70%
over 24–40 minutes and this condition was maintained for
fourminutes.The chromatographic parameters were adapted
from Yang et al. [20] method.
To identify and suggest the presence of components in
the leaf extract of C. xanthocarpa, peak retention times
were studied and a thorough comparison between sample
and standard references was made. The standard com-
pounds used were gallic acid (200𝜇g/mL), chlorogenic acid
(200𝜇g/mL), quercetin (200𝜇g/mL), luteolin (100𝜇g/mL),
isoquercetin (100 𝜇g/mL), quercitrin (100 𝜇g/mL), theo-
bromine (35 𝜇g/mL), caffeic acid (35 𝜇g/mL), and caffeine
(35 𝜇g/mL), preparedwith ethanol 50% (v/v). Extract samples
and references standards were analyzed in triplicate.
2.5. Evaluation of Blood Pressure and Possible Action
Mechanisms of the Campomanesia xanthocarpa Extract
2.5.1. Animals. Male Wistar rats were used that were three
months old and purchased from Universidade Federal de
Santa Maria. They were kept in cages with a controlled
temperature (22∘C), 12 hour dark/light cycle, food, and water
ad libitum.
The experimental protocols followed the International
Principles for Research Involving Animals (Geneva), Brazil-
ian legislation by Law No. 11.794/2008 (Procedures for the
Scientific Use of Animals), and Decree 24.645/34 (animal
rights) and were approved by the Ethics Committee on
Animal Use (ECAU) of the university (Protocol 017/2014).
After all of the protocols, the animals were sacrificed
using the guillotine while still under the effects of the
anesthesia.
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2.5.2. Hemodynamic Parameters. The rats were submitted to
surgery for catheterization of the carotid artery (to mea-
sure the hemodynamic parameters) and the jugular vein
(for extract and drugs administration), with polyethylene
catheters (PE10 Clay-Adams) filled with heparinized saline
(50 IU/mL), under anesthesia with urethane (1.4 g/kg, i.p.),
which was assessed by responsiveness to painful stimuli and
supplemented when necessary [21]. The arterial catheter was
connected to a pressure transducer coupled to an analog
digital converter (Biopac Systems MP150, Inc.; CA).
2.5.3. Extract Curve. For evaluation of the extract effects on
hemodynamic parameters, a rising curve was done, after 30
minutes of stabilization. A total of 25, 50, 75, 100, 125, 150,
175, and 200mg/kg of extract cumulative were administered,
with a volume of 0.2mL of saline; each dosewas administered
15 minutes after the other (𝑛 = 8). Systolic blood pressure
(SBP), diastolic blood pressure (DBP), and heart rate (HR)
were recorded over approximately 3 hours.
2.5.4. Evaluation of Possible ActionMechanisms of the Extract.
For the investigation of mechanisms involved in the extract
hypotensive action, certain drugs were tested after 30 min-
utes of stabilization: N
𝜔
-nitro-L-arginine methyl ester (L-
NAME), an nitric oxide (NO) synthesis inhibitor (30mg/kg,
𝑛 = 6); losartan, AT1 receptor antagonist of angiotensin II
(10mg/kg, 𝑛 = 6); and hexamethonium, a ganglionic blocker
(20mg/kg, 𝑛 = 6) [21–23]. After drug administration, a new
stabilization period was conducted, and then the extract (5
to 100mg/kg) was administered, with the exception of the
L-NAME protocol that used doses of 5 to 25mg/kg because
50mg/kg of the extract after administration of this drug
caused a sharp decrease in blood pressure, inducing some
animals’ death. Hemodynamic records of SBP, DBP, and HR
were taken.
2.5.5. Drugs. All drugs and reagents used were purchased
from Sigma Chemical Co. (St. Louis, MO, United States).
2.6.MolecularModeling Studies. Computational studies were
performed with chlorogenic acid and quercetin, components
determined in aqueous extract, to obtain information which
aided in the understanding of the biological activity. Density
functional theory (DFT) B3LYP/6-311G∗, based in gas phase
methodology, evaluable in Spartan’08 for Windows software
(Wavefunction Inc., Irvine, United States) was used for geom-
etry optimization and conformational analysis. The geom-
etry of compounds was optimized followed by submission
to systematic conformational analysis with a torsion angle
increment set of 30∘ in the range of 0–360∘.The lowest energy
conformer for chemical structure was saved in a mol2 file
before use in the docking studies.
The structure of angiotensin II type 1 receptor, AT1R
encoded PDB ID: 4YAY [24], was downloaded from the
protein data bank (PDB) before performing the docking
studies, and this 3D structure was prepared by removing the
watermolecules and adding polar hydrogens using Autodock
Tools 1.5.6 [25]. Using iGemdock software [26], docking
studies were performed in which the individual binding
site of chlorogenic acid and quercetin were assessed and
submitted to docking in the active site of the AT1R. Dock-
ing calculations were performed at drug screening docking
accuracy setting with GA parameters set for population
size, generation, and number of solutions as 200, 70, and 3,
respectively, with a Gemdock score function of hydrophobic
and electrostatic (1 : 1 preference). iGemdock software was
used to infer the pharmacological interactions between the
biological receptors and compounds studied.
2.7. Statistical Analysis. Data were expressed as the mean ±
standard deviation (SD), values were analyzed by one-way
ANOVA for repeated measures and Tukey’s post hoc, and
𝑝 < 0.05 was considered significant.
3. Results
3.1. Characterization of Plant and Extracts. The value of the
total phenolic compounds found in the analysis of C. xantho-
carpa extract was 3.7360mgGAE/mL (relative standard devi-
ation 2.87%), and the flavonoid content was 2.5070mgRE/g
(relative standard deviation 3.45%).
3.2. HPLC-DAD Analysis. The results showed the presence
of many compounds in the crude extract of C. xanthocarpa.
In Figure 1, it is possible to observe the complexity of plant
matrix, whose constituents are being detected along the
chromatographic run; in this case, the detection at 340 nm
was focused in phenolic compounds. Compared to the
reference standards, the similarity between retention times,
besides UV spectra for chromatographic peaks, is indicative
for the presence of gallic acid (compound 1), chlorogenic acid
(compound 2), and quercetin (compound 3). In another assay
(Figure 2), aiming to evaluate the xanthine derivatives and
caffeic acid by performing the detection at 280 nm,we suggest
the presence of theobromine (compound 8) in the medicinal
plant studied. It is important to mention that the peaks were
evaluated using UV-DAD detection, whose UV profile data
were thoroughly studied in order to confirm the chemical
composition suggested (Figure 3).
3.3. Evaluation of Blood Pressure and Possible Action
Mechanisms of C. xanthocarpa Extract
3.3.1. Evaluation of Hemodynamic Parameters in the Dosage
Curve of C. xanthocarpa Extract. In the dose-administration
curve, it can be observed that blood pressure decreased with
the extract from 50mg/kg in a dose-dependent manner. SBP
and DBP decreased from 126.71±9.26 to 68.14±9.99mmHg
and from 81.85 ± 12.58 to 32.14 ± 14.89mmHg, respectively
(Figure 4(a)). Heart rate also decreased in the presence of the
extract from 50mg/kg to 200mg/kg (Figure 4(b)).
3.3.2. Evaluation of the Possible Action Mechanism of C.
xanthocarpa Extract. As expected, L-NAME (Figure 5(a))
caused a hypertensive peak of 73.2–59mmHg (SBP–DBP),
but when the extract was administered the blood pressure
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Table 1: Central pharmacological interactions (Van derWaals, H-bond, and electrostatic) of compounds and residues involved in the binding
site of ACE-I with normal and applying the residues consensus analysis.
Compounds TYR 35 TRP 84 THR 88 SER 105 VAL 108 SER 109 ARG∗ 167 ILE 288
Chlorogenic acid
Van der Waals −5.5 −13.0 0.0 −5.7 −7.2 0.0 −6.3 −6.9
H-Bond 0.0 0.0 −2.5 0.0 0.0 −4.2 −4.1 0.0
Electrostatic 0.0 0.0 0.0 0.0 0.0 0.0 −1.9 0.0
Quercetin
Van der Waals −4.2 −19.0 0.0 −6.9 −0.2 −5.1 0.0 −8.2
H-Bond −5.0 0.0 0.0 −2.1 0.0 0.0 −15.7 0.0
Electrostatic 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
∗Confirmed by residue consensus analysis.
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Figure 1: Representative chromatogram obtained in the analysis by HPLC-DAD wherein (a) phenolic standards are (1) gallic acid, (2)
chlorogenic acid, (3) quercetin, and (4) luteolin; (b) phenolic standards are (5) vitexin, (6) isoquercetin, and (7) quercitrin; and (c) C.
xanthocarpa aqueous extract, detection at 340 nm.
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Figure 2: Representative chromatogram obtained in the analysis by HPLC-DAD wherein (a) xanthine standards and caffeic acid are (8)
theobromine, (9) caffeic acid, and (10) caffeine and (b) C. xanthocarpa aqueous extract, detection at 280 nm.
decreased to normal levels, suggesting that NO synthase
mechanism is not involved in the hypotensive effect of the
extract. The heart rate decreased in the presence of L-NAME
after administration of the extract at doses of 20 and 25mg/kg
(Figure 5(b)).
Losartan (Figure 5(c)) and hexamethonium (Figure 5(e))
decreased blood pressure from 121.4 ± 7.56 × 84.2 ± 12.87 to
91.2 ± 11.23 × 49.4 ± 5.27mmHg and 118.75 ± 7.41 × 74 ±
4.76 to 101.75 ± 7.18 × 50.25 ± 10.53mmHg, respectively.
After administration of these drugs, extract administration
occurred, and no alterations to blood pressure were detected;
this may mean that the hypotensive action of the extract
can be implicated in the AT1R mechanism and sympathetic
ganglionic blockade. In the losartan protocol, with 10mg/kg
of the extract, the heart rate decreased from 339 ± 28.41 to
274.4 ± 30.16 (Figure 5(d)). With hexamethonium, the heart
rate was not altered (Figure 5(f)).
3.4. MolecularModeling Studies. Molecular modeling studies
were performed on two of the main components of aqueous
extract from C. xanthocarpa: chlorogenic acid and quercetin
(Figure 6). Docking was run using the conformer of minimal
energy of chemical structure generated by Spartan, and
results from the interaction are shown in Table 1. The active
Evidence-Based Complementary and Alternative Medicine 5
19
8
31
2
23
8
21
4
27
4
32
5
0
100
200
300
400
500
(m
AU
)
250 300 350200
(nm)
(a)
19
8
31
1
25
7
23
9
21
2
29
1
32
6
24
9
0
500
1000
1500
2000
2500
3000
(m
AU
)
250 300 350200
(nm)
(b)
19
7
21
0
31
5
26
0
20
0
21
5
28
8
32
1
0
50
100
150
200
250
300
350
(m
AU
)
250 300 350200
(nm)
(c)
21
1
31
2
26
1
21
4
29
1
32
3
0
250
500
750
(m
AU
)
250 300 350200
(nm)
(d)
0
250
500
750
1000
1250
1500
1750
23
7
28
2
20
3
25
5
35
4
(m
AU
)
250 300 350200
(nm)
(e)
19
6
24
1
31
0
28
3
20
7
25
6
35
0
30
1
0
500
1000
1500
2000
2500
3000
(m
AU
)
250 300 350200
(nm)
(f)
24
3
36
1
20
3
27
3
250 300 350200
(nm)
0
25
50
75
(m
AU
)
(g)
24
1
33
2
20
4
27
2
250 300 350200
(nm)
0
1
2
3
4
5
6
(m
AU
)
(h)
Figure 3: UV spectra obtained fromDAD analysis applied to each chromatographic peak for standard references and C. xanthocarpa extract.
(a) UV spectra for compound 1 (gallic acid) in standard reference; (b) UV spectra for compound 1 (gallic acid) in the extract; (c) UV spectra
for compound 2 (chlorogenic acid) in standard reference; (d) UV spectra for compound 2 (chlorogenic acid) in the extract; (e) UV spectra
for compound 3 (quercetin) in standard reference; (f) UV spectra for compound 3 (quercetin) in the extract; (g) UV spectra for compound
8 (theobromine) in standard reference; and (h) UV spectra for compound 8 (theobromine) in the extract.
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Figure 4: Evaluation of hemodynamic parameters in the dosage curve of C. xanthocarpa extract. (a) Register of the systolic and diastolic
blood pressure with different administration of extract doses. (b) Heart rate during curve dosage of C. xanthocarpa extract. ∗𝑝 < 0.05 versus
control (𝑛 = 8).
interactions between the compound and AT1R are shown in
Figure 7.
4. Discussion
Many phytochemical studies provide evidence of the pres-
ence of phenolic compounds and flavonoids in the Campo-
manesia genus [27, 28]. Some demonstrate higher values than
the findings in our study, which can be justified by several
factors, including seasonality, the type of soil in which the
plant was grown, water availability, nutrient supply, minerals,
development stage, temperature, ultraviolet radiation, induc-
tion by mechanical action stimuli, or pathogens [29].
Because phenolic compounds and flavonoids are known
to have many pharmacological activities, the C. xanthocarpa
extract may have promising biological effects. The phenolic
compounds gallic acid, quercetin, and chlorogenic acid have
several biologically related uses, such as analgesic, antidi-
abetic, anti-inflammatory, antiobesity, antioxidant, cardio-
protective, hypotensive, and neuroprotective effects [30–33].
These substances, observed in our study, have already been
shown in other studies with plants of the Myrtaceae family
[34–36].
Phenolic compounds, mainly flavonoids, beyond other
biological activities, act as antioxidants, not only for their
ability to donate hydrogen or electrons but also because
of their stable intermediate radical, which prevents the
oxidation of several food molecules, particularly lipids [28].
The well-recognized antioxidant properties of flavonoids
resulted in the interest in their potential role in prevention
of cardiovascular diseases [37].
The antioxidant properties of natural products depend
not only on polyphenol content but also on type. For instance,
quercetin and catechin demonstrate the greatest antioxidant
properties in vitro [38]. Studies have shown the effect of
quercetin on the prevention and treatment of cardiovascular
diseases, cancer, and renal and hepatic insufficiency [39].
These actions could be linked to the ability of themaintenance
of vascular integrity due to the sequestration of free radi-
cals and the inhibition of lipid peroxidation, lipoxygenase,
cyclooxygenase, and phospholipase A2 activity. They also
inhibit LDL oxidation, platelet aggregation, and C kinase
protein activity and promote vasodilatation [31]. Thus, the
high content of quercetin in C. xanthocarpa extract can be
related to its hypotensive action.
Chlorogenic acid and gallic acid are present in the studied
extract. These substances are phenolic compounds with
important biological properties beyond antioxidant action;
they also have insulin-sensitizing activities, reduce hyper-
glycemia via severalmechanisms, and have a cardioprotective
effect [32, 40].
Other secondary plant metabolites are alkaloids, the
most diverse group found in living organisms with an array
of structure types, biosynthetic pathways, and pharmaco-
logical activities [41]. The alkaloid theobromine (3,7-dimeth-
ylxanthine; 3,7-DMX) derived from caffeine metabolism has
amoderate diuretic effect on the kidneys, causes mild cardiac
stimulation, and acts on the central nervous system and
cardiovascular, renal, and digestive systems [42, 43]. It also
increases serumHDL-cholesterol concentrations that may be
important in CVD prevention [44]. However, this is the first
time that this compound is reported in C. xanthocarpa; its
main existence is related to other species such as Paullinia
cupana, Ilex paraguariensis, Coffea arabica,Theobroma cacao,
and Camelia sinensis [45–48].
The dose nature of effects of the extract on blood pressure
and heart rate of the rats suggests a cumulative action of the
active substances present in the leaves of the plant. Thus,
we can attribute the hypotensive effect of C. xanthocarpa to
its phenolic and alkaloid compounds. Despite some reports,
the present study is the first that describes the hypotensive
activity of this extract, which is extremely important because
the incidence of hypertension and use of medicinal plants
have been increasing worldwide, generating future potential
natural therapies.
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Figure 5: Evaluation of hemodynamic parameters in rats treated withC. xanthocarpa extract in the presence of different drug administration.
(a) Register of the systolic and diastolic blood pressure with extract in the presence of L-NAME (30mg/kg). (b) Register of heart rate during
L-NAME protocol. (c) Register of the systolic and diastolic blood pressure with extract in the presence of losartan (20mg/kg). (d) Register of
heart rate during losartan protocol. (e) Register of the systolic and diastolic blood pressure with extract in the presence of hexamethonium
(10mg/kg). (f) Register of heart rate during hexamethonium protocol. ∗𝑝 < 0.05 versus control and #𝑝 < 0.05 versus drug (𝑛 = 6).
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Figure 6: Chemical structure of chlorogenic acid (a) and quercetin (b).
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Figure 7: Binding of chlorogenic acid and quercetin in the active site of AT1R (PDB: 4YAY). Graphic visualization obtained using PyMOL
(v.0.99).
To investigate themechanism of the hypotensive action of
C. xanthocarpa, drugs were administered before the extract.
L-NAME is an analog of arginine competing for NO synthase
and causes a hypertensive peak, resulting in the gross inhibi-
tion of NO synthesis [49]. It is widely used in experiments
with rats as a model of systemic hypertension [50, 51]. Thus,
that the extract decreased blood pressure after administration
of this drug suggests that NO synthase mechanism is not
involved in the hypotensive effect.
Losartan acts through blocking the renin-angiotensin
system by selectively antagonizing the receptors for angiot-
ensin II, subtype AT1R. Previous evidence shows that the
blockade of angiotensin AT1R results in reduced oxidative
stress, inflammatory markers, and fibrinolysis inhibition
[52].
Hexamethonium is potent and essentially devoid of neu-
romuscular blocking activity by a nicotinic receptor-blocking
agent that blocks ion channels of the autonomic ganglia,
resulting in blockage of the outputs of the sympathetic path-
ways [53, 54]. Due to its charged structure, hexamethonium
peripherally administered is presumed not to enter the brain
and therefore is commonly used to distinguish peripheral
ganglionic responses in vivo from those that arise centrally
[53].
As the extract did not alter blood pressure after adminis-
tration of losartan and hexamethonium, it can be suggested
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that the hypotensive action of the extract implicates the AT1R
mechanism and sympathetic ganglionic blockade.
The docking procedure was aimed to identify individual
poses of chlorogenic acid and quercetin, components of C.
xanthocarpa extract, that may bind to the AT1R active site.
Chlorogenic acid was chosen for the docking analysis for its
recognized antihypertensive activity [33], and quercetin was
selected because this compound showed downregulation of
the AT1R in the kidneys [55].
The empirical scoring function of iGemDOCK is the esti-
mated sum total of Van der Waals, H-bond, and electrostatic
energy. In this case, the comparison of chlorogenic acid lig-
and poses chlorogenic acid and quercetin structures revealed
similar conformations and conserved molecular recognition
modes for antagonists and inverse agonists toward AT1R
[24]. Chlorogenic acid and quercetin showed an affinity
energy of −91.44 and 88.15 Kcalmol−1. Chlorogenic acid
showed Van derWaals, H-bond, and electrostatic interaction
values of −76.11, −13.35, and −1.98 Kcalmol−1, respectively,
and quercetin showed only Van der Walls and H-bond at
−62.01 and 26.14 Kcalmol−1, respectively. No electrostatic
interaction of quercetin and AT1R was observed.
According to the data of docking experiments, main
interactions occurwith the residues TYR35, TRP 84, THR88,
SER 105, VAL 108, SER 109, ARG 167, and ILE 288 (Figure 7).
After the postscreening analysis using residue consensus
analysis, ARG 167 was detected as the main residue involved
in this ligand-receptor binding (with a Z-score of −1.12 and
WPharma of 1.00) to chlorogenic acid only.The ARG 167 and
TRP 84 residues are the same observed in the docking study
Zhang et al. [24] performed, suggesting the active site of AT1R
studied.
A model generated from chlorogenic acid suggests the
interaction of H-bond, Van der Waals, and electrostatic
types with ARG 167. The carboxylic acid attached to the
cyclohexane ring of chlorogenic acid’s chemical structure
was located in the same spatial region as determined by the
docking of the same moiety from the telmisartan or tetrazole
ring from losartan [24]. The main type of interaction was a
Van der Waals interaction with the TYR 35, TRP 84, SER
105, VAL 108, ARG 167, and ILE 288 residues. In the case
of chlorogenic acid, there is a molecular distance of 2.82 A˚
between ARG 167 and a carboxylic acid moiety attached to
the hexane ring and the 2.82 A˚ of hydrogen from hydroxyl
group with THR 88, and 3.01 A˚ of hydroxyl and SER 109 of
AT1R were observed.
Some main interactions of the quercetin ligand and
AT1R were H-bonds with ARG 167 and Van der Waals with
the THR 84 and ILE 288 residues. Quercetin showed an
interaction with the hydroxyl moiety attached to aromatic
ring TYR 35; this group has distances of 2.8 and 3.10 A˚
between hydroxyl groups and the flavonol nucleus. Carbonyl
moiety from flavonols showed a molecular distance of 2.70 A˚
of the nitrogen atom from the tetrazole ring of ARG 167.
These data suggest that chlorogenic acid and quercetin, which
are important components in the plant extract, may be the
compounds causing the interaction of cardiac AT1R.
Based on these results, it can be concluded that the aque-
ous extract of C. xanthocarpa presents expressive phenolic
and flavonoid content. Additionally, the presence of chloro-
genic and gallic acid, quercetin, and theobromine in the
extract was determined. It was hypothesized that two con-
stituents of the plant may be attributed to its AT1R inter-
action. These substances already have a clinical potential
described that can assist in the investigation of the phar-
macological properties of this plant. However, the acute
administration of the aqueous extract ofC. xanthocarpa has a
dose-dependent hypotensive effect in normotensive rats, and
we suggest that this action may be mediated through the
renin-angiotensin system by AT1R blockade and a sympa-
thetic autonomic response.
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